Sangamo Therapeutics (SGMOQ) EBT (2010 - 2025)

Sangamo Therapeutics has reported EBT for 16 years, with the latest figure at -$38.0 million in Q4 2025.

• On a quarterly basis, EBT fell 59.39% year-over-year to -$38.0 million in Q4 2025; TTM through Dec 2025 was -$123.5 million, a 25.88% decrease from a year earlier, with the FY2025 full-year figure at -$123.5 million, down 25.88% from the prior year.
• EBT was -$38.0 million for Q4 2025 at Sangamo Therapeutics, down from -$35.1 million in the prior quarter.
• The five-year high for EBT was $21.3 million in Q1 2023, with the low at -$120.8 million in Q2 2023.
• Average EBT over 5 years is -$42.7 million, with a median of -$43.5 million recorded in 2022.
• The sharpest annual moves came in 2021 and 2023: EBT plunged 3645.24% in 2021, then surged 148.56% in 2023.
• Over 5 years, EBT stood at -$37.6 million in 2021, then slumped by 37.67% to -$51.7 million in 2022, then decreased by 17.12% to -$60.6 million in 2023, then jumped by 60.67% to -$23.8 million in 2024, then slumped by 59.39% to -$38.0 million in 2025.
• The last three EBT figures came in at -$38.0 million (Q4 2025), -$35.1 million (Q3 2025), and -$20.0 million (Q2 2025), per Business Quant data.